{"id":103976,"date":"2025-02-12T11:30:00","date_gmt":"2025-02-12T11:30:00","guid":{"rendered":"https:\/\/en.econostrum.info\/uk\/?p=103976"},"modified":"2025-02-12T08:56:11","modified_gmt":"2025-02-12T08:56:11","slug":"vitality-discount-on-wegovy-and-mounjaro","status":"publish","type":"post","link":"https:\/\/en.econostrum.info\/uk\/vitality-discount-on-wegovy-and-mounjaro\/","title":{"rendered":"Vitality Launches Exclusive Discount on Wegovy and Mounjaro for Eligible UK Members"},"content":{"rendered":"\n<p>Vitality has become the first health insurer in the UK to offer its members discounted weight-loss treatments, including <strong>Wegovy<\/strong> and <strong>Mounjaro<\/strong>, through private health cover. Eligible members can receive up to 20% off these medications for up to a year, depending on their <strong>body mass index (BMI)<\/strong> and weight-related health conditions.<\/p>\n\n\n\n<p>Obesity is a growing concern in the UK, with significant health and economic implications. According to government estimates, obesity costs the <strong><a href=\"https:\/\/www.nhs.uk\/\" target=\"_blank\" rel=\"noopener\">NHS <\/a>\u00a36.5 billion annually<\/strong>, contributing to serious conditions such as cardiovascular disease and type 2 diabetes. As new <strong>GLP-1-based weight-loss drugs<\/strong> gain popularity, private insurers are beginning to incorporate them into their health plans.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Vitality&#8217;s weight-loss initiative and eligibility criteria<\/strong><\/h2>\n\n\n\n<p>Vitality, the UK\u2019s third-largest health insurer after <strong>Bupa<\/strong> and <strong>Axa<\/strong>, has introduced this programme as part of its broader strategy to encourage healthier lifestyles. According to the company, members can apply for the discount by completing a <a href=\"https:\/\/en.econostrum.info\/uk\/dwp-changes-pip-claimants-health-conditions\/\" data-type=\"post\" data-id=\"103592\">health <\/a>profile through the <strong>Vitality app<\/strong>. Those with a BMI of <strong>35 or higher<\/strong> and weight-related health risks will be eligible for the medication pathway.<\/p>\n\n\n\n<p>In addition to discounted access to <strong>Wegovy<\/strong> and <strong>Mounjaro<\/strong>, eligible members will receive coaching from a <strong>dietitian<\/strong> and access to the programme for up to <strong>12 months<\/strong>. These drugs, which belong to the <strong>GLP-1<\/strong> class, mimic a gut hormone that suppresses appetite and have been shown to help users achieve significant weight loss.<\/p>\n\n\n\n<p>The initiative builds on Vitality\u2019s existing weight-loss programme, which uses reward-based incentives to encourage members to adopt healthier habits. According to the insurer, nearly <strong>48% of enrolled members<\/strong> in the programme achieve a weight reduction of around <strong>5%<\/strong>. This can lead to further benefits such as lower insurance excess fees and other rewards.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>High demand and cost of GLP-1 weight-loss drugs<\/strong><\/h2>\n\n\n\n<p>Weight-loss drugs such as <strong>Wegovy<\/strong> and <strong>Mounjaro<\/strong> have become increasingly popular, but their cost remains a barrier. <strong>Wegovy<\/strong>, produced by <strong>Novo Nordisk<\/strong>, costs between <strong>\u00a3139 and \u00a3269 per month<\/strong> in the <a href=\"https:\/\/en.econostrum.info\/uk\/uk-households-receive-water-bill-discounts\/\" data-type=\"post\" data-id=\"103926\">UK<\/a>, depending on the dosage. It was approved for NHS use in <strong>2023<\/strong> and has demonstrated <strong>up to 15% body weight reduction<\/strong> after a year.<\/p>\n\n\n\n<p><strong>Mounjaro<\/strong>, developed by <strong>Eli Lilly<\/strong>, was approved by the <strong>NHS<\/strong> in <strong>2023<\/strong> and has shown even greater weight-loss results in clinical trials, averaging <strong>20% reduction in body weight<\/strong>. The medication costs <strong>\u00a3139 per month<\/strong> at online pharmacies, with a maximum annual cost of <strong>\u00a31,435<\/strong>.<\/p>\n\n\n\n<p>Despite growing demand, private health insurers have been slow to cover these medications. According to <strong>Health Affairs<\/strong>, fewer than <strong>20% of large US companies<\/strong> currently include weight-loss drug coverage in their insurance plans.<\/p>\n\n\n\n<p>Dr <strong>Katie Tryon<\/strong>, chief commercial director at <strong>Vitality<\/strong>, stated that while traditional health risks such as smoking and alcohol use are declining, <strong>obesity, mental health issues, and musculoskeletal conditions<\/strong> are on the rise. This initiative reflects a shift in the insurance industry\u2019s approach to <strong>preventative healthcare<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vitality has become the first UK health insurer to offer discounted access to Wegovy and Mounjaro, two of the most sought-after weight-loss medications. Eligible members can receive up to 20% off for a year, alongside expert dietary support. <\/p>\n","protected":false},"author":10,"featured_media":103978,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-103976","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33","no-featured-image-padding"],"_links":{"self":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts\/103976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/comments?post=103976"}],"version-history":[{"count":2,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts\/103976\/revisions"}],"predecessor-version":[{"id":103979,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts\/103976\/revisions\/103979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/media\/103978"}],"wp:attachment":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/media?parent=103976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/categories?post=103976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/tags?post=103976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}